RedHill Biopharma Ltd. (RDHL)
$0.915
Rating:
Recommendation:
Neutral
| Symbol | RDHL |
|---|---|
| Price | $0.915 |
| Beta | 1.930 |
| Volume Avg. | 2.20M |
| Market Cap | 48.733M |
| Shares () | - |
| 52 Week Range | 0.62-11.18 |
| 1y Target Est | - |
| DCF Unlevered | RDHL DCF -> | |
|---|---|---|
| DCF Levered | RDHL LDCF -> | |
| ROE | -379.42% | Strong Sell |
| ROA | -53.95% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 1941.55% | Strong Buy |
| P/E | - | |
| P/B | 4.82 | Strong Buy |
Latest RDHL news
About
Download (Excel)RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.